Literature DB >> 17684738

Digoxin and mortality in atrial fibrillation: a prospective cohort study.

Pär Hallberg1, Johan Lindbäck, Bertil Lindahl, Ulf Stenestrand, Håkan Melhus.   

Abstract

OBJECTIVE: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study showed that rhythm-control treatment of patients with atrial fibrillation (AF) offered no survival advantage over a rate-control strategy. In a subgroup analysis of that study, it was found that digoxin increased the death rate [relative risk (RR) = 1.42), but it was suggested that this may have been attributable to prescription of digoxin for patients at greater risk of death, such as those with congestive heart failure (CHF). No study has investigated a priori the effect of digoxin on mortality in patients with AF. This study aimed to address this question.
METHODS: Using data from the Registry of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA), we studied the 1-year mortality among patients admitted to coronary care units with AF, CHF, or AF+CHF with or without digoxin (n = 60,764) during 1995-2003. Adjustment for differences in background characteristics and other medications and treatments was made by propensity scoring.
RESULTS: Twenty percent of patients with AF without CHF in this cohort were discharged with digoxin. This group had a higher mortality rate than the corresponding group not given digoxin [adjusted RR 1.42 (95% CI 1.29-1.56)], whereas no such difference was seen among patients with CHF with or without AF, although these patients had a nearly three-times higher mortality.
CONCLUSION: The results suggest that long-term therapy with digoxin is an independent risk factor for death in patients with AF without CHF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684738     DOI: 10.1007/s00228-007-0346-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  40 in total

Review 1.  Invited commentary: propensity scores.

Authors:  M M Joffe; P R Rosenbaum
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

2.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

Review 3.  Digoxin. A neurohormonal modulator in heart failure?

Authors:  M Gheorghiade; D Ferguson
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

4.  Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation.

Authors:  K K Koh; K S Kwon; H B Park; S H Baik; S J Park; K H Lee; E J Kim; S H Kim; S K Cho; S S Kim
Journal:  Am J Cardiol       Date:  1995-01-01       Impact factor: 2.778

Review 5.  Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of the angiotensin Converting Enzyme) trials.

Authors:  J Tauke; S Goldstein; M Gheorghiade
Journal:  Prog Cardiovasc Dis       Date:  1994 Jul-Aug       Impact factor: 8.194

6.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Authors:  Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

7.  Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort.

Authors:  Ulf Stenestrand; Lars Wallentin
Journal:  Arch Intern Med       Date:  2003-04-28

8.  The effect of digoxin on the quality of life in patients with heart failure.

Authors:  Ellis Lader; Debra Egan; Sally Hunsberger; Rekha Garg; Susan Czajkowski; Frances McSherry
Journal:  J Card Fail       Date:  2003-02       Impact factor: 5.712

9.  Comorbidity and myocardial dysfunction are the main explanations for the higher 1-year mortality in acute myocardial infarction with left bundle-branch block.

Authors:  Ulf Stenestrand; Fariborz Tabrizi; Johan Lindbäck; Anders Englund; Mårten Rosenqvist; Lars Wallentin
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

10.  Use of cardiovascular drugs in an older Swedish population.

Authors:  P Wills; J Fastbom; C B Claesson; C Cornelius; M Thorslund; B Winblad
Journal:  J Am Geriatr Soc       Date:  1996-01       Impact factor: 5.562

View more
  24 in total

1.  Appropriateness of serum digoxin levels.

Authors:  Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Giorgio Brocco; Gian Cesare Guidi
Journal:  Eur J Clin Pharmacol       Date:  2007-09-16       Impact factor: 2.953

2.  Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study.

Authors:  Mintu P Turakhia; Pasquale Santangeli; Wolfgang C Winkelmayer; Xiangyan Xu; Aditya J Ullal; Claire T Than; Susan Schmitt; Tyson H Holmes; Susan M Frayne; Ciaran S Phibbs; Felix Yang; Donald D Hoang; P Michael Ho; Paul A Heidenreich
Journal:  J Am Coll Cardiol       Date:  2014-08-19       Impact factor: 24.094

3.  Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?

Authors:  Laurent Fauchier; Guillaume Laborie; Nicolas Clementy; Dominique Babuty
Journal:  Card Fail Rev       Date:  2016-05

4.  Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.

Authors:  James V Freeman; Kristi Reynolds; Margaret Fang; Natalia Udaltsova; Anthony Steimle; Niela K Pomernacki; Leila H Borowsky; Teresa N Harrison; Daniel E Singer; Alan S Go
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-11-20

Review 5.  Comorbidity of atrial fibrillation and heart failure.

Authors:  Liang-Han Ling; Peter M Kistler; Jonathan M Kalman; Richard J Schilling; Ross J Hunter
Journal:  Nat Rev Cardiol       Date:  2015-12-10       Impact factor: 32.419

Review 6.  Atrial fibrillation in heart failure: current treatment of patients with remodeled atria.

Authors:  Hans-Ruprecht Neuberger; Jan-Christian Reil; Oliver Adam; Ulrich Laufs; Christian Mewis; Michael Böhm
Journal:  Curr Heart Fail Rep       Date:  2008-12

7.  Prognostic impact of early ventricular fibrillation in patients with ST-elevation myocardial infarction treated with primary PCI.

Authors:  Marina M Demidova; J Gustav Smith; Carl-Johan Höijer; Fredrik Holmqvist; David Erlinge; Pyotr G Platonov
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-12

8.  Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction.

Authors:  Sebastiano Virgadamo; Richard Charnigo; Yousef Darrat; Gustavo Morales; Claude S Elayi
Journal:  World J Cardiol       Date:  2015-11-26

9.  Safety of Intravenous Diltiazem in Reduced Ejection Fraction Heart Failure with Rapid Atrial Fibrillation.

Authors:  Mohamad Badr Jandali
Journal:  Clin Drug Investig       Date:  2018-06       Impact factor: 2.859

Review 10.  Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?

Authors:  Jeffrey B Washam; Manesh R Patel
Journal:  Curr Cardiol Rep       Date:  2018-09-12       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.